Evolution of the Average Target: Abbott Laboratories

Evolution of the Average Target - Abbott Laboratories

Evolution of the Target Price: Abbott Laboratories

Evolution of the Target Price - Abbott Laboratories

Changes in Analyst Recommendations: Abbott Laboratories

c0e7bbd8d450fea39e1b974fd6d52726.vxFRHtLBGcJMVPtJOEA8HARh8cI1Yt07JuMhxtW8diY.10thKratX_YlObYLVTRwd04Wh5FWB7NqYdFtqr_-Mh_IZj5HgqQvliY8qg~2155e5316ad86467a18332f0cc2c14c1
11:17pm Leerink Partners Upgrades Abbott Laboratories to Outperform From In Line, $124 Price Target MT
11/11 BofA Adjusts Price Target on Abbott Laboratories to $125 From $115 MT
28/10 Abbott Laboratories Shares Fall After Argus Downgrade MT
27/10 Argus Downgrades Abbott Laboratories to Hold From Buy MT
23/10 Abbott Laboratories' 2026 Guidance Cut Driven by Diabetes, Electrophysiology Portfolio, RBC Says MT
23/10 Jefferies & Co Adjusts Abbott Laboratories Price Target to $130 From $135 MT
22/10 RBC Trims Price Target on Abbott Laboratories to $125 From $130, Keeps Outperform Rating MT
22/10 Leerink Partners Adjusts Price Target on Abbott Laboratories to $106 From $109 MT
22/10 BTIG Adjusts Price Target on Abbott Laboratories to $125 From $134 MT
22/10 Wells Fargo Adjusts Price Target on Abbott Laboratories to $119 From $112 MT
22/10 JPMorgan Adjusts Price Target on Abbott Laboratories to $118 From $120 MT
22/10 TD Cowen Adjusts Price Target on Abbott Laboratories to $118 From $135 MT
21/10 Abbott Laboratories' Established Pharma Unit Undervalued on Biosimilars Potential, UBS Says MT
07/10 Barclays Initiates Coverage on Abbott Laboratories With Overweight Rating, $120 Price Target MT
05/10 Evercore ISI Adjusts Price Target on Abbott Laboratories to $124 From $120, Keeps Outperform Rating MT
02/10 Rothschild & Co Redburn Upgrades Abbott Laboratories to Buy From Neutral, Adjusts PT to $127 From $119 MT
02/10 Rothschild & Co Redburn Upgrades Abbott Laboratories to Buy From Neutral, Adjusts PT to $127 From $119 MT
02/10 Analyst recommendations: Airbnb, Hewlett Packard Enterprise, Fair Isaac, Nike… Zonebourse
21/08 TD Cowen Adjusts Price Target on Abbott Laboratories to $135 From $115, Maintains Buy Rating MT
13/08 Citigroup Adjusts Price Target on Abbott Laboratories to $125 From $112, Maintains Buy Rating MT
13/08 Wolfe Research Upgrades Abbott Laboratories to Outperform From Peer Perform, PT is $130 MT
29/07 UBS Adjusts Price Target on Abbott Laboratories to $125 From $135, Maintains Buy Rating MT
28/07 Rothschild & Co Redburn Adjusts PT on Abbott Laboratories to $119 From $126, Maintains Neutral Rating MT
23/07 Daiwa Securities Adjusts Price Target on Abbott Laboratories to $103 From $92, Maintains Neutral Rating MT
22/07 Leerink Partners Adjusts Price Target on Abbott Laboratories to $109 From $106, Maintains Market Perform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+13.81%
+5.59%
+7.15%
+19.78%
+11.47%
+4.66%
+2.68%
+30.16%
+19.59%
+16.47%
Average +13.13%
Weighted average by Cap. +11.99%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
104.48USD
Average target price
118.91USD
Spread / Average Target
+13.81%
High Price Target
130.00USD
Spread / Highest target
+24.43%
Low Price Target
100.00USD
Spread / Lowest Target
-4.29%

Analyst Consensus Detail

Analyst consensus - Abbott Laboratories

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Abbott Laboratories
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Abbott Laboratories
  1. Stock Market
  2. Stocks
  3. ABT Stock
  4. Consensus Abbott Laboratories